Found 1 Presentation For Request "1307P"
1307P - Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations
- Michele Milella (Verona, Italy)
Abstract
Background
g
Methods
We analyzed the impact of exposure to olaparib on OS from the start of I-line treatment in a cohort of 114 Italian g
Results
In the entire cohort, OS from the start of I-line treatment for metastatic disease was significantly (p=0.02) longer in pts who had been exposed to olaparib in any treatment line (n=53; Table); similar results were obtained analyzing only pts who had received olaparib in its current indication (n=43). Since previous surgery and response to I-line chemotherapy were strong independent predictors of OS at multivariate analysis, we analyzed pts who were diagnosed with stage IV (M+, n=87) disease and pts who did not experience PD as best response to I-line CHT (no PD, n=94), separately. A statistically significant difference in OS favoring g
Any olaparib mOS (mos; 95% CI) No (n=61) 16 (12-20) 0.02 Yes (n=53) 34 (24-44) No (n=47) 14 (11-18) 0.0025 Yes (n=40) 34 (25-43 No (n=43) 17 (8-25) 0.049 Yes (n=50) 34 (24-43) No (n=35) 16 (12-20) 0.019 Yes (n=38) 34 (24-44)
Conclusions
In g
Legal entity responsible for the study
The authors.
Funding
Fondazione Italiana per la ricerca sulle Malattie del Pancreas (FIMP).
Disclosure
M. Milella: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Pfizer, Novartis, Ipsen, Viatris; Financial Interests, Personal and Institutional, Research Grant: Roche. S. Lonardi: Financial Interests, Personal, Advisory Board: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, MSD, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb; Financial Interests, Personal, Invited Speaker: Pierre-Fabre, GlaxoSmithKline; Financial Interests, Institutional, Invited Speaker: Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, Bristol Myers Squibb. M. Reni: Financial Interests, Personal, Advisory Board: Panavance, Viatris, Sotio, Servier, MSD, AstraZeneca, Celgene, Lilly. All other authors have declared no conflicts of interest.